Press release from Business Wire
Gilead Sciences to Release First Quarter 2013 Financial Results on Thursday, May 2, 2013
<p class='bwalignc'> <i><b>Conference Call and Webcast to Follow</b></i> </p>
Thursday, April 25, 2013
Gilead Sciences to Release First Quarter 2013 Financial Results on Thursday, May 2, 201316:30 EDT Thursday, April 25, 2013
FOSTER CITY, Calif. (Business Wire) -- Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2013 financial results will be released on Thursday, May 2, at 4:05 p.m. Eastern Time. At 4:30 p.m. Eastern Time, Gilead's management will host a conference call to discuss the company's financial results for the first quarter and provide a general business update. The conference call will be accessible via the Internet from the company's website.
To access the webcast link, log on to www.gilead.com. Please connect to the company's website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. Alternatively, please call 1-866-318-8617 (U.S.) or 1-617-399-5136 (international) and dial the participant passcode 81259571 to access the call. Telephone replay will be available approximately two hours after the call through 11:59 p.m. Eastern Time, May 5, 2013. To access the replay, please call 1-888-286-8010 (U.S.) or 1-617-801-6888 (international) and dial the participant passcode 57408121. The webcast will be archived on www.gilead.com for one year.
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Asia Pacific.
For more information on Gilead Sciences, please visit www.gilead.com or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).
Gilead Sciences, Inc.
Patrick O?Brien, 650-522-1936 (Investor Relations)